HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
DDR2
discoidin domain receptor tyrosine kinase 2
Chromosome 1 Β· 1q23.3
NCBI Gene: 4921Ensembl: ENSG00000162733.20HGNC: HGNC:2731UniProt: Q16832
140PubMed Papers
22Diseases
1Drugs
27Pathogenic Variants
FUNCTIONAL ROLE
KinaseReceptor
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
protein autophosphorylationprotein tyrosine kinase collagen receptor activitypeptidyl-tyrosine phosphorylationregulation of bone mineralizationspondyloepimetaphyseal dysplasia-short limb-abnormal calcification syndromeSpondyloepimetaphyseal dysplasia - short limb - abnormal calcificationWarburg-Cinotti syndromemetastatic colorectal cancer
✦AI Summary

DDR2 (discoidin domain receptor tyrosine kinase 2) is a cell surface receptor tyrosine kinase that binds fibrillar collagen and regulates tissue remodeling processes 1. The protein functions as a collagen-activated receptor that promotes extracellular matrix remodeling through upregulation of matrix metalloproteinases and facilitates cell migration and proliferation 2. In skeletal development, DDR2+ stem cells contribute to calvarial mineralization through a distinct form of endochondral ossification, with DDR2+ cell expansion occurring as a maladaptive response to other stem cell depletion in craniosynostosis 1. DDR2 serves as a biomarker for cardiac fibroblasts and plays roles in cardiac tissue remodeling 3. In pathological contexts, DDR2 promotes cancer progression through multiple mechanisms: in ovarian cancer, stromal DDR2 enhances metastasis by regulating glycolytic metabolism and extracellular matrix protein secretion, particularly LOXL2 4, while DDR2-regulated arginase activity in cancer-associated fibroblasts promotes collagen production and tumor invasion 2. In hepatocellular carcinoma, DDR2 activation through Ξ²-catenin signaling contributes to epithelial-mesenchymal transition and metastasis 5. DDR2 is also being investigated as a potential therapeutic target in lung cancer treatment 6.

Sources cited
1
DDR2+ stem cells contribute to calvarial mineralization and craniosynostosis pathogenesis
PMID: 37730988
2
DDR2 regulates arginase activity in cancer-associated fibroblasts promoting collagen production
PMID: 37996700
3
DDR2 serves as a biomarker for cardiac fibroblasts
PMID: 29987445
4
Stromal DDR2 promotes ovarian cancer metastasis through metabolism regulation and LOXL2 secretion
PMID: 37527178
5
DDR2/Ξ²-catenin activation promotes hepatocellular carcinoma metastasis
PMID: 36471363
6
DDR2 is a potential therapeutic target in lung cancer
PMID: 40076671
Disease Associationsβ“˜22
spondyloepimetaphyseal dysplasia-short limb-abnormal calcification syndromeOpen Targets
0.79Strong
Spondyloepimetaphyseal dysplasia - short limb - abnormal calcificationOpen Targets
0.75Strong
Warburg-Cinotti syndromeOpen Targets
0.65Moderate
metastatic colorectal cancerOpen Targets
0.55Moderate
colorectal cancerOpen Targets
0.54Moderate
colorectal neoplasmOpen Targets
0.49Moderate
Abnormality of the skeletal systemOpen Targets
0.48Moderate
Dupuytren ContractureOpen Targets
0.48Moderate
hepatocellular carcinomaOpen Targets
0.47Moderate
neoplasmOpen Targets
0.44Moderate
gastrointestinal stromal tumorOpen Targets
0.39Weak
pancreatic carcinomaOpen Targets
0.39Weak
bile duct carcinomaOpen Targets
0.39Weak
neurodegenerative diseaseOpen Targets
0.38Weak
gastric carcinomaOpen Targets
0.37Weak
breast ductal adenocarcinomaOpen Targets
0.37Weak
extranodal nasal NK/T cell lymphomaOpen Targets
0.37Weak
hemangioblastomaOpen Targets
0.37Weak
nodular melanomaOpen Targets
0.37Weak
superficial spreading melanomaOpen Targets
0.37Weak
Spondyloepimetaphyseal dysplasia, short limb-hand typeUniProt
Warburg-Cinotti syndromeUniProt
Pathogenic Variants27
NM_006182.4(DDR2):c.2254C>T (p.Arg752Cys)Likely pathogenic
Spondyloepimetaphyseal dysplasia-short limb-abnormal calcification syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 752
NM_006182.4(DDR2):c.1829T>C (p.Leu610Pro)Pathogenic
Warburg-cinotti syndrome|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 610
NM_006182.4(DDR2):c.2048+1G>ALikely pathogenic
not provided
β˜…β˜†β˜†β˜†2026
NM_006182.4(DDR2):c.1711G>T (p.Glu571Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 571
NM_006182.4(DDR2):c.1021C>T (p.Arg341Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 341
NM_006182.4(DDR2):c.1382C>G (p.Ser461Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 461
NM_006182.4(DDR2):c.186-1G>ALikely pathogenic
not provided
β˜…β˜†β˜†β˜†2024
NM_006182.4(DDR2):c.565+1G>ALikely pathogenic
not provided
β˜…β˜†β˜†β˜†2023
NM_006182.4(DDR2):c.417+1G>TLikely pathogenic
not provided
β˜…β˜†β˜†β˜†2023
NM_006182.4(DDR2):c.2408_2409del (p.Glu803fs)Pathogenic
not provided
β˜…β˜†β˜†β˜†2023β†’ Residue 803
NM_006182.4(DDR2):c.681del (p.Gly228_Leu229insTer)Pathogenic
not provided
β˜…β˜†β˜†β˜†2023β†’ Residue 228
NM_006182.4(DDR2):c.2105C>T (p.Ser702Phe)Likely pathogenic
Fetal growth restriction
β˜…β˜†β˜†β˜†2023β†’ Residue 702
NM_006182.4(DDR2):c.2125C>T (p.Arg709Ter)Pathogenic
not provided|Ovarian serous cystadenocarcinoma
β˜…β˜†β˜†β˜†2023β†’ Residue 709
NM_006182.4(DDR2):c.1831C>T (p.Arg611Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2022β†’ Residue 611
NC_000001.11:g.162775664_162775665insTTTTTTTTTTTTTTTTTTTTNNNNNNNNNNACCTCATGATCCACCCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCGCGCCCGGCCGGAATGATTTTCTTPathogenic
not provided
β˜…β˜†β˜†β˜†2022
NM_006182.4(DDR2):c.337G>A (p.Glu113Lys)Pathogenic
Spondyloepimetaphyseal dysplasia-short limb-abnormal calcification syndrome|not provided
β˜…β˜†β˜†β˜†2022β†’ Residue 113
NM_006182.4(DDR2):c.111del (p.Gly38fs)Pathogenic
not provided
β˜…β˜†β˜†β˜†2022β†’ Residue 38
NM_006182.4(DDR2):c.1045C>T (p.Gln349Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2022β†’ Residue 349
NM_006182.4(DDR2):c.2140C>T (p.Arg714Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2022β†’ Residue 714
NM_006182.4(DDR2):c.768T>A (p.Tyr256Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2022β†’ Residue 256
View on ClinVar β†—
Drug Targets1
REGORAFENIBApproved
Discoidin domain-containing receptor 2 inhibitor
colorectal cancer
Related Genes
ITGA2Protein interaction98%COL1A1Protein interaction86%COL3A1Protein interaction86%COL5A1Protein interaction86%COL11A1Protein interaction86%SHC1Protein interaction71%
Tissue Expression6 tissues
Ovary
100%
Heart
73%
Lung
46%
Brain
22%
Liver
12%
Bone Marrow
2%
Gene Interaction Network
Click a node to explore
DDR2ITGA2COL1A1COL3A1COL5A1COL11A1SHC1
PROTEIN STRUCTURE
Preparing viewer…
PDB2WUH Β· 1.60 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.38Moderately Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.27 [0.20–0.38]
RankingsWhere DDR2 stands among ~20K protein-coding genes
  • #3,275of 20,598
    Most Researched140 Β· top quartile
  • #910of 1,025
    FDA-Approved Drug Targets1
  • #1,889of 5,498
    Most Pathogenic Variants27
  • #1,767of 17,882
    Most Constrained (LOEUF)0.38 Β· top 10%
Genes detectedDDR2
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Lung Cancer-Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature).
PMID: 40076671
Int J Mol Sci Β· 2025
1.00
2
Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis.
PMID: 15591520
Gut Β· 2005
0.90
3
A multi-stem cell basis for craniosynostosis and calvarial mineralization.
PMID: 37730988
Nature Β· 2023
0.80
4
Biomarkers for the identification of cardiac fibroblast and myofibroblast cells.
PMID: 29987445
Heart Fail Rev Β· 2019
0.70
5
DDR2-regulated arginase activity in ovarian cancer-associated fibroblasts promotes collagen production and tumor progression.
PMID: 37996700
Oncogene Β· 2024
0.60